View More Recent Stories

Nov 6, 2019 01:15PM Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Oct 30, 2019 04:05PM Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019
Oct 24, 2019 11:00AM Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Oct 8, 2019 11:00AM Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019
Sep 26, 2019 05:14PM Personalis, Inc. (PSNL) Receives New Order from VA's Million Veteran Program
Sep 26, 2019 04:05PM Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M
Sep 12, 2019 04:08PM Personalis, Inc. (PSNL) Announces Karin Eastham to Board
Sep 12, 2019 04:07PM Personalis Appoints Karin Eastham to Its Board of Directors
Sep 9, 2019 08:00AM Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Aug 26, 2019 04:32PM Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 13, 2019 04:02PM Personalis Reports Second Quarter 2019 Financial Results
Aug 7, 2019 08:00AM Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Aug 1, 2019 04:05PM Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications
Jul 30, 2019 08:00AM Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019
Jun 24, 2019 04:05PM Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option
Jun 20, 2019 06:14AM Personalis, Inc. (PSNL) Prices 7.92M Share IPO at $17/Sh
Jun 19, 2019 09:10PM Personalis Prices Initial Public Offering of Common Stock
View More Recent Stories